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SUMMARY
Autoimmune diseases of major salivary glands include Sjögren’s syndrome and a complex of disorders classified as immunoglobulin G4-related 
diseases. These pathologies are characterised by an autoimmune reaction mediated by T-helper lymphocytes that targets the ducts of exocrine 
glands in Sjögren’s syndrome and glandular parenchyma in immunoglobulin G4-related diseases. Immunoglobulin G4-related diseases repre-
sent recently introduced multi-organ diseases that also involve the salivary glands. However, the morbid conditions once known as Mikulicz’s 
disease and Kuttner’s tumour were recently considered as two variants of immunoglobulin G4-related diseases affecting the major salivary 
glands ( immunoglobulin G4-related sialadenitis). This review briefly summarises the pathogenesis and clinical features of autoimmune diseases 
of the major salivary glands, focusing on the diagnostic and therapeutic role of sialendoscopy.
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RIASSUNTO
Le patologie autoimmuni delle ghiandole salivari maggiori comprendono la sindrome di Sjögren e l’insieme di condizioni morbose rac-
colte sotto il nome di patologie IgG4-correlate. Tanto la sindrome di Sjögren quanto le patologie IgG4-correlate sono caratterizzate da 
una reazione autoimmune mediata dai linfociti T-Helper il cui bersaglio è rappresentato dai dotti delle ghiandole esocrine nella sindrome 
di Sjögren e dal parenchima ghiandolare nelle malattie IgG4-correlate. Queste ultime, di introduzione relativamente recente, coinvolgo-
no solitamente molti organi tra cui le ghiandole salivari. Negli ultimi anni patologie un tempo note come malattia di Mikulicz e tumore 
di Kuttner sono state classificate come le patologie IgG4-correlate limitate alle ghiandole salivari maggiori e denominate scialoadeniti 
IgG4-correlate. Questa breve revisione riassume la patogenesi e le principali caratteristiche cliniche delle ghiandole salivari maggiori 
sottolineando il potenziale ruolo diagnostico e terapeutico delle scialoendoscopia.
PAROLE CHIAVE: Tumore di Kuttner • Malattia di Mikulicz • Patologie IgG4-Correlate • Scialoadeniti IgG4-Correlate • Sindrome di 
Sjögren • Stenosi Duttale • Scialoendoscopia
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Introduction
Salivary gland diseases include neoplasms and non-neo-
plastic disorders such as viral parotitis, sialolithiasis and 
chronic non-lithiasic sialadenitis. Autoimmune diseases 
are responsible for a small share of chronic, non-lithiasic 
inflammatory disorders of major salivary glands. In these 
conditions, the parenchyma of salivary glands, salivary 
ducts, or both represent the target of an attack carried out 
by the immune system against its own tissues, through 
autoantibodies and T cells. Sjögren’s syndrome (SS) and 
immunoglobulin G4-related diseases (IgG4-RD) are the 
main chronic autoimmune sialadenitis 1 2.
SS attacks the exocrine glands, specifically the salivary and 
lacrimal tissue, and CD4+ lymphocytes play the main role 
in the autoimmune process. IgG4-RD are newly described 
fibro-inflammatory conditions that often present as nodular 
lesions that can affect nearly every organ system 1. In IgG4-
RD, the target of the autoimmune attack is the connective 
tissue and the inflammatory cell infiltration is composed of 
IgG4-positive plasma cells, CD4+ and CD8+ T cells. In re-
cent years, both Mikulicz’s disease (MD) and the so-called 
Kuttner’s tumour (KT) were classified in the group of IgG4-
RD and considered as variations of IgG4 RD affecting sali-
vary tissue (IgG4-related sialadenitis or IgG4-RS) 3.
The aim of this review is summarise the characteristics of 
the autoimmune diseases that affect the salivary glands, 
analysing the potential role of sialendoscopic techniques 
in the diagnosis and treatment of these conditions.
SjÖgren’s syndrome (SS)
SS may be defined as a chronic autoimmune inflammatory 
exocrinopathy affecting the salivary and lacrimal glands. 
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The dysfunction of exocrine glands is usually accompa-
nied by a multitude of extraglandular manifestations 4.
SS may occur as primary or secondary form. Primary SS, 
with or without extraglandular involvement, occurs in the 
absence of another underlying rheumatic disorder, where-
as secondary SS is associated with another autoimmune 
disease, such as systemic lupus erythematosus, rheuma-
toid arthritis, or scleroderma. Given the overlap of SS with 
many other rheumatic disorders, it is sometimes difficult 
to determine whether a clinical manifestation is solely 
a consequence of SS or is due to one of its overlapping 
disorders. These primary and secondary types occur with 
similar frequency, but sicca complex symptoms seem to 
be more severe in primary form 5, 6.
Primary SS is an autoimmune disorder characterised 
by lymphocytic infiltrates with destruction of exocrine 
glands and systemic production of autoantibodies against 
ribonucleoprotein particles SS-A/Ro and SS-B/La. The 
infiltrating cells (T- and B-cells, dendritic cells) interfere 
with salivary production at several points, starting a vi-
cious circle and causing the salivary glands to become 
sites of chronic inflammation 4.
Despite extensive studies, the underlying cause of SS and 
its pathogenesis remains controversial. It is thought that 
environmental factors can trigger inflammation in indi-
viduals with a genetic predisposition, configuring a multi-
factorial disease 7.
Primary SS is strongly associated with HLA-DR3 and the 
linked genes B8, and DQ2, and C4A null gene. Within the 
primary SS group, those with anti-La represent a subset 
that show an even more striking association with HLA 3. 
This suggests that the anti-La-positive patients with SS 
may be the most homogeneous subgroup, both clinically 
and immunogenetically. Anti-Ro is associated with DR2 
and the linked DQ1 gene, as well as with DR3, and this 
may reflect the wider diagnostic associations of this anti-
body. Rheumatoid arthritis with secondary SS is associ-
ated with DR4 rather than DR3 8-11.
Viruses are viable candidates as environmental triggers, 
although no single virus has been implicated and the trig-
gering mechanisms is still unknown. Epstein-Barr virus, 
HTLV-1, human herpesvirus 6, HIV, hepatitis C virus and 
cytomegalovirus may have a role and clinical manifesta-
tions of sicca syndrome are frequently seen in patients in-
fected with HIV, HTLV-1, and hepatitis C 12-14. Damage 
and/or cell death due to viral infection may provide trig-
gering antigens to toll-like receptors in or on dendritic or 
epithelial cells, which, by recognising pathogen-associat-
ed patterns, are activated and begin producing cytokines, 
chemokines and adhesion molecules. As T and B lympho-
cytes migrate into the gland, they themselves become acti-
vated by dendritic and epithelial cells, thereafter acting as 
antigen-presenting cells. Expressed antigens include SSA/
Ro, SSB/La, alpha-fodrin and beta-fodrin, and cholinergic 
muscarinic receptors. Dendritic cell triggering by immune 
complexes formed from SSA–anti-SSA (or other immune 
complexes) may propagate the ongoing innate and ac-
quired immune activation 11-15.
SS is one of the most common autoimmune rheumatic 
diseases with a prevalence around 1% according to the 
revised American-European Consensus Group (AECG) 
criteria 16. There is general agreement that it is a disease of 
middle-aged or elderly women (mean age of onset 45–55 
years, male/female ratio 1:9) 4 11.
Clinically, most individuals with SS present with sicca symp-
toms (xerophthalmia and xerostomia), that are expression 
of chronic exocrinopathy. The lack of saliva in the mouth 
and the absence of a normal ‘pool’ of saliva underneath the 
tongue causes an increase in the rate of caries and may pro-
mote oral candidosis. In more severe cases, the tongue is 
atrophic, fissured or even ulcerated. Parotid glands are fre-
quently swollen. Exocrine glands other than the salivary and 
lacrimal glands may be affected. Dry skin and dry hair are 
symptoms frequently elicited on direct questioning. About 
30% of patients have diminished vaginal secretions and may 
present with dyspareunia. Involvement of the gastrointesti-
nal tract leads to reflux oesophagitis or gastritis owing to a 
lack of protective mucus secretion is also possible 4-7 11.
SS is a systemic disease. About 70% of patients complain 
of fatigue that may be misdiagnosed whereas arthritis, 
with characteristics similar to those seen in rheumatoid 
arthritis, occurs in about 30% of subjects 11. The renal fea-
tures of SS include interstitial nephritis, leading to renal 
tubular acidosis, and membranous glomerulonephritis due 
to circulating immune complex disease (more common 
in the secondary SS). The incidence of significant renal 
disease of around 5%, but subclinical renal features of dis-
ease rises to around 30% 17. Interstitial pneumonitis deter-
mined by an interstitial infiltrate of lymphocytes around 
the bronchioles may cause function abnormalities found 
in approximately 25% of patients with SS 18. Although 
vasculopathies such as Raynaud’s phenomenon and con-
genital heart block are also frequently observed, these dis-
orders assume minor clinical significance 11. Conversely, 
neurological involvement is quite rare (1%), but may 
manifest as multiple sclerosis-like syndrome 19. Finally,it 
has long been known that patients with primary SS have 
a 44-fold increased risk of mucosa-associated lymphoid 
tissue (MALT) type B cell lymphoma 20.
A number of classification criteria for SS were designed, 
primarily for clinical research studies, but are also used to 
guide clinical diagnoses. The revised AECG criteria for 
classification of Sjögren’s syndrome 16, summarised in Ta-
ble I, were proposed in 2002 and are the most commonly 
used criteria for diagnosis of SS. A new set of classifica-
tion criteria has been developed by the Sjögren’s Inter-
national Collaborative Clinical Alliance (SICCA) inves-
tigators and accepted as a provisional criteria set by the 
American College of Rheumatology (ACR) in 2012 21.
Diagnostic workup in the suspicion of SS usually include 
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the blood tests listed in the revised AECG criteria. Fur-
thermore, patients with SS frequently present leucopenia, 
thrombocytopenia, high ESR and anti-nuclear antibodies.
The classical histological feature of SS at minor salivary 
gland biopsy is of at least one ‘focus’ of 50 or more (pre-
dominantly CD4+) T lymphocytes per high-powered field 
clustered around a salivary duct (periductal focal lympho-
cytic infiltrates). Histology reports sometimes describe 
a generalised scattering of inflammatory cells across the 
gland usually described as a ‘chronic sialadenitis’. The 
report may conclude that this is ‘compatible with SS’. In 
fact, chronic sialadenitis can be found in normal individu-
als and this should be classed as a negative biopsy 1 4 7 11 16.
AECG criteria order to objectively assess xerophthalmia 
through simple, economic tests such as Rose Bengal stain-
ing and the Schirmer test, which can be used to strongly 
support or refute the suspicion of SS 22. Conversely, the 
tests recommended to objectify the signs of xerostomia, 
except for the poor standardised sialometry, are par-
ticularly expensive (salivary scintigraphy) and not very 
specific (sialography) imaging techniques. Sialographic 
changes in parotid glands affected by SS were accurately 
described and, with regards to chronic sialadenitis, clas-
sified into punctate, globular, cavitary and destructive 
sialectasia of the acinar and ductal system. These four 
sialectasic changes are thought to represent increasing 
glandular damage caused by an autoimmune reaction 23. 
Sialendoscopy, according to AECG criteria, is not listed 
as a recommended examination to assess salivary gland 
involvement in SS. The reason for this exclusion is proba-
bly due to historical reasons: the revised AECG criteria, in 
fact, date to 2002 whereas sialendoscopy still represents a 
relatively new procedure. However, this technique allows 
endoscopic transluminal visualisation of major salivary 
glands and offers a mechanism for diagnosing and treat-
ing both inflammatory and obstructive pathologies related 
to the ductal system, and thus like sialography potentially 
adequate to recognise the ductal abnormalities accompa-
nying SS 24.
In the literature, there is little experience about the role 
of sialendoscopy in SS. Some authors report the presence 
of hyperaemia at the level of main and the second-order 
salivary ducts, with evidence of a vascular pattern demon-
strating perivascular inflammation and congestion 25. It is 
possible that this endoscopic appearance, also observed 
in recurrent parotitis, could characterise the initial phases 
of SS, whereas the pale, little vascularised appearance of 
the ductal wall expresses the subsequent progression of 
the disease, in which parenchymal tissue is replaced by 
fibrosis 24 25. Obstructive mucous plugs are frequently ob-
served in the ductal tree. The presence of these obstruc-
tions causes saliva stagnation and inflammation upstream 
of the obstruction, which is probably responsible for the 
occasional parotid swelling and pain 25 26. However, stric-
ture formation was found to be the major cause of ductal 
obstruction by other authors. Jager, et al. and De Luca, 
et al. reported the presence of stricture in the majority of 
salivary glands affected by SS explored in their study 27 28. 
Microlithiasis, related to the subsequent inflammatory 
episodes 29, is observed mainly in the advanced stages of 
the disease in which the fibrous replaced and subverted 
the entire gland. Our research group is currently investi-
gating a possible role of sialendoscopy in diagnosis of SS 
by analysing the expression of IL-17 and IL-23 in saliva 
and ductal lavage collected during the surgical procedure.
The therapy for SS is based on drugs aimed to modulate 
the autoimmune response. Traditional immunomodula-
tory drugs such as low-dose steroids, methotrexate, ciclo-
sporin and azathioprine show no benefit, while there is 
some evidence to support the use of hydroxychloroquine 
sulphate, although there is no evidence of a direct effect 
on salivary or lacrimal flow 6 30-32. Thus, although biologic 
Table I. American–European Consensus Group Classification criteria for Sjögren’s syndrome. Diagnosis of primary Sjögren’s syndrome requires four of six 
criteria; in addition, either criterion number 5 or criterion number 6 must be included. Sjögren’s syndrome can be diagnosed in patients who have no sicca 
symptoms if three of the four objective criteria are fulfilled. Secondary Sjögren’s syndrome is diagnosed when, in the presence of a connective-tissue disease, 
symptoms of oral or ocular dryness exist in addition to criterion 3, 4, or 5.
1. Ocular symptoms Dry eyes for more than 3 months
Foreign-body sensation
Use of tear substitutes more than 3 times daily
2. Oral symptoms Feeling of dry mouth
Recurrently swollen salivary glands
Frequent use of liquids to aid swallowing
3. Ocular signs Schirmer test performed without anesthesia (< 5 mm in 5 min)
Positive vital dye staining results
4. Oral signs Abnormal salivary scintigraphy findings
Abnormal parotid sialography findings
Abnormal sialometry findings (unstimulated salivary flow < 1.5 mL in 15 min)
5. Positive minor salivary gland biopsy findings (focus score ≥1)
6. Positive anti–SSA or anti–SSB antibody results
Exclusions: any patient with past head and neck radiation treatment, hepatitis C infection, acquired
immunodeficiency disease (AIDS), pre-existing lymphoma, sarcoidosis, graft versus host disease, use of anticholinergic drugs.
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agents represent promising treatments 33-35, the current man-
agement of xerostomia and xerophthalmia is still based on 
topical treatments (tear and saliva substitutes) 36 and sialog-
ogues such as pilocarpine and cevimeline 37-39.
During sialendoscopy, a semi-rigid miniaturised endoscope 
is inserted into the salivary duct after dilating the papilla 
and driven in the ductal system under constant irrigation 40. 
Sterile saline solution is the fluid of choice for the irriga-
tion of salivary ducts, but corticosteroid solutions can also 
be used 24 40-42 Thus, a diagnostic procedure alone causes 
relevant dilation of the entire ductal system. On the other 
hand, the use of interventional sialendoscope with work-
ing channels allows the concomitant treatment of strictures, 
mucus plugs and sialoliths, contributing to alleviate com-
plaints in patients affected by inflammatory disease 24 43-45. 
Recent clinical experience suggested that sialendoscopy 
may alleviate the oral symptoms of SS by restoring sali-
vary function 25-28. Jager, et al. conducted a randomised 
study of 20 patients with SS oral symptoms who were ran-
domly assigned to the nonintervention control group or to 
the sialendoscopy group. In patients undergoing sialendos-
copy, unstimulated and stimulated saliva flow, Clinical Oral 
Dryness Score, Xerostomia Inventory Score, and EULAR 
Sjogren’s Syndrome Patient Reported Index score showed 
a significant improvement of symptoms at 1 and 8 weeks 
after the procedure 27. Although a positive effect of sialen-
doscopy on xerostomia cannot be assessed with a few, 
small case series, these promising results suggest that sia-
loendoscopy could be a viable technique to treat obstruc-
tive salivary gland diseases related to SS that is refractory 
to conventional management.
IgG4-related sialadenitis (IgG4-RS)
IgG4-RD are newly described fibro-inflammatory condi-
tions that often presents as tumefactive lesions affecting 
several districts. Hamano, et al. first recognised IgG4-RD 
in 2001, after a connection between elevated serum IgG4 
levels and inflammatory mass lesions in the pancreas 
causing autoimmune pancreatitis 46. However, an initial 
consensus statement regarding diagnosis of IgG4-RD was 
reached only in 2011 during the first international sympo-
sium for IgG4-RD 47.
The head and neck region is the second most common 
site for presentation of IgG4-RD after the pancreas and 
some pseudotumoural diseases of unknown pathogenesis, 
including MD and KT, have been attributed to IgG4-RD 
during the last 10 years 48-55. Identification of IgG4-posi-
tive plasma cells in both KT and MD propelled renewed 
interest in these diseases, and fueled re-analyses of the 
classification of inflamed salivary glands 56.
The exact aetiology of IgG4-RS is unknown and no 
known role of the IgG4 molecule has been identified. 
IgG4 itself normally represents the smallest fraction of 
IgG subclasses (< 5%). It has an amino acid variance in the 
hinge region allowing it to split and randomly combine with 
other half molecules, creating asymmetric bispecific anti-
bodies with two different antigen-binding sites. For this spe-
cial feature, IgG4 scarcely forms immune complexes, binds 
Fc-receptors and complements component with low affinity. 
Thus, its ability to initiate immune responses is limited 2 3.
It is postulated that the inflammatory and fibrotic process-
es that drive IgG4-RS are propagated by a combination of 
T helper (Th) 2 cells and regulatory T cells (Treg cells). 
This is contrary to most autoimmune disorders where po-
larised Th1 and/or Th17 subsets are responsible for the 
inflammatory process 2 3 47.
Clinical data on IgG4-RS are increasingly reported. Cur-
rently, it is believed that this condition preferentially af-
fects middle-aged males presenting with persistent pa-
rotid and/or submandibular gland swelling, unilaterally or 
bilaterally.
The disorder that was identified by Kuttner in 1896 57 
commonly involves one or both submandibular glands, 
clinically presenting as hard tumour-like masses with ten-
dency to nodular swelling that can be confounded with 
malignant forms. The disease is often associated with 
microlithiasis. Histological sections reveal preservation 
of the lobular architecture, marked lymphoplasmacytic 
inflammation, large irregular lymphoid follicles with 
expanded germinal centers and acinar atrophy without 
prominent lymphoepithelial lesions. Characteristically, 
prominent cellular interlobular fibrosis due to activated 
fibroblasts and infiltration of lymphocytes and IgG4-pos-
itive-stained plasma cells is observed. Eosinophil infiltra-
tion and obliterative phlebitis are frequent 56.
MD, first described in 1888 58, refers to idiopathic, bilateral, 
painless, symmetrical and persistent swelling of the lacri-
mal, parotid and submandibular glands. Because MD and 
primary-SS are histologically similar, MD has long been 
considered as a subtype of SS. Upon haematoxylin-eosin 
staining, lacrimal or salivary gland specimens from MD 
showed severe mononuclear cell infiltration and lymphoid 
follicles around the ductal and acinar cells. The infiltration of 
numerous IgG4-positive plasmacytes near acinar and ductal 
cells and around lymphoid follicles allows differentiating 
MD from SS 51. Therefore, the presence of IgG4-positive 
plasmacytes in the inflammatory infiltration suggests that 
MD and KT are only two different phenotypes of IgG4-RS.
A comparison between clinical and histological features 
of the two phenotypes of IgG4-RS and SS is summarised 
in Table II.
Clinically, xerostomia is inconstant in IgG4-RS, involving 
approximately 30% of patients. Autoimmune pancreatitis, 
sclerosing cholangitis and asthma are frequently associat-
ed conditions (15-30%). Lacrimal gland involvement, as 
well as sinonasal disorders and cervical lymphadenopathy 
(70%), are frequent coexisting conditions 3.
Imaging studies of salivary glands show a pattern of non-
specific features in MD phenotype of IgG4-RS. On US 
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examination of the affected glands, hypoechoic areas 
with hyperechoic lines creating a reticular pattern that is 
a common finding in patients affected by SS. On the con-
trary, a nodular pattern with duct enlargement and micro-
lithiasis is often observed in the disorder once known as 
KT. Computerised tomography and magnetic resonance 
imaging have lower diagnostic accuracy compared to ul-
trasonography 2 3 51-56.
Biopsy of the affected gland is necessary to formulate a diag-
nosis of IgG4-RS, although lip biopsy has been proposed as 
an alternative technique 59. There are three main histopatho-
logical hallmarks for IgG4-RD: infiltrates of IgG4+ plasma-
cytes, intense fibrosis and obliterative phlebitis. However, 
the exact histological findings vary greatly depending on 
the tissue affected and clinical presentation. Currently, his-
tologic diagnosis of IgG4-RD is based primarily on IgG4 
positive to IgG containing cell ratio and, secondarily, on the 
number of IgG4 positive cells per high power field. A ratio 
of IgG4 to IgG that is higher than 50% and the confirmation 
of at least 30 IgG4-positive cells per high-power field are 
considered to be highly suggestive of IgG4-RD 60.
Laboratory tests on blood can confirm the diagnosis. Pa-
tients affected by IgG4-RD show significantly higher total 
IgG, IgG2, IgG4 and IgE. In addition, eosinophil counts 
are usually increased and hypocomplementaemia is fre-
quent. In particular, elevated serum IgG4, even if neither 
present in all patients with histologically proven IgG4-RD 
nor specific for it, can be a supplementary tool in the di-
agnosis of IgG4-RD 61. Serum IgG4 concentration > 135 
mg/dl-1 have been defined as a threshold value for diagno-
sis 61. Furthermore, it was observed that IgG4 serum con-
centration correlates with reduction of saliva production 
and glandular fibrosis, suggesting that IgG4 concentration 
in serum can represent a useful marker to follow the evo-
lution of the disease and efficacy of treatment 56.
In the literature, there are very few publications focusing on 
medical treatment of IgG4-RS, although all authors indicate 
systemic steroid therapy as first-line treatment and pred-
nisone represents the most used drug. In the past decades, 
in fact, the good responsiveness to steroids was considered a 
distinctive clinical feature of MD compared to SS 51.
Steroid therapy, weighted according to the activity of the 
disease and body mass, is usually long-term and the initial 
dose is gradually tapered after 2-4 weeks of starting therapy. 
Long-term glucocorticoid treatment seems to significantly 
improve symptoms related to reduced salivary secretion 
conferring, according to some studies, recovery of histo-
logical abnormalities. Some authors have emphasised the 
role of early steroid therapy to improve outcomes in patients 
with IgG4-RS. Salivary secretion rate, indeed, seems to de-
crease with histological changes related to a delayed inter-
vention 62. Conversely, the role of other immunosuppressive 
agents such as azathioprine, methotrexate, or mycopheno-
late mofetil is still controversial and understudied.
To the best of our knowledge, there are no reports about 
sialendoscopy performed in patients affected by IgG4 re-
lated sialadenitis. However, we believe that this technique 
will be useful in the management of patients suffering 
from IgG4-RD. Although it is unlikely that this method 
can replace the role of the biopsy for diagnostic purposes, 
sialendoscopy is a potential tool in the treatment of si-
aladenitis. Endoscopic techniques, in fact, as is the case 
Table II. Comparison between SS and IgG4-RS.
Features SS IgG4-RS
MD phenotype KT phenotype
Clinical Gender (female:male) 9:1 1:2.5
Glands involvement Both parotids and 
submaxillary glands
Both parotids and 
submaxillary glands
submaxillary glands
Bilateral/unilateral Bilateral Bilateral Often unilateral
Appearance Usually transient
swelling
Persistent symmetrical 
swelling
Persistent nodular swelling
Salivary impairment Severe Mild
Response to steroids Limited Good
Histological Fibrosis Inconstant, mild Constant, intense
Obliterative phlebitis Absent frequent
IgG4+ plasmacytes Absent >30–50 hpf
Serological Serum IgG4 levels Normal High
Serum IgE levels Normal High
Anti-Ro(SSA)/
Anti-La(SSB)
High rate Absent
Imaging Ultrasound Inhomogeneity 
hypoechoic areas and 
hyperechoic lines and 
spots
Inhomogeneity hypoechoic 
areas and hyperechoic 
lines and spots
Nodular, smooth contour mass 
with hypoechoic foci scattered 
against a heterogeneous 
background.
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in other chronic sialadenitis, could eliminate microlithi-
asis and debris thorough rinsing or using microforceps 
and basket, also allowing the treatment of eventual ductal 
stenosis using hydrostatic pressure or high-pressure bal-
loons. Furthermore, the intraductal administration of anti-
inflammatory drugs, while poorly studied at present, may 
be an alternative to systemic steroids in the future.
Conclusions
The role of sialendoscopy in the treatment of autoimmune 
chronic sialadenitis is currently understudied, mainly due 
to the recent worldwide diffusion of this technique.
The outcomes of a few preliminary trials, however, are 
particularly encouraging and deserve to be verified in ran-
domised controlled trials with a larger sample and longer 
follow-up period.
The discussion between otolaryngologists and rheumatol-
ogists should also be more incisive so that sialendoscopy 
and sialography can be considered as useful techniques 
for diagnosis and staging of autoimmune diseases of the 
salivary glands. Furthermore, rheumatologists should 
consider a minimally invasive technique such as interven-
tional sialendoscopy for management of patients suffering 
from autoimmune diseases of the major salivary glands 
who do not derive benefit from conventional therapies.
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